Clinical development: gene therapy IND cleared in the U.S.

The Mucolipidosis Type IV (ML4) Foundation announced FDA IND clearance for the first U.S. clinical trial of an investigational gene therapy for mucolipidosis type IV (MLIV), an ultra-rare inherited neurological disorder with fewer than 100 known children worldwide. The clearance sets the stage for initiating U.S. study activity after earlier development steps outside the U.S. and supports patient access planning for a population with no approved therapies. The IND action is a key procedural milestone for gene therapy programs where the regulatory pathway can be especially demanding due to manufacturing and long-term considerations.